Regent Pacific operates as an investment firm headquartered in Hong Kong, engaging in innovative corporate and strategic investments primarily within the healthcare and life sciences sectors. The company's major investment lies in Plethora Solutions Holdings plc, a wholly-owned subsidiary. Plethora specializes in pharmaceuticals and focuses on the commercialization of its flagship product Fortacin™, the first EU-approved topical prescription for premature ejaculation. In early 2018, Fortacin™ was successfully launched in key European markets including France, Germany, Italy, Spain, and Portugal.
Regent Pacific
Headquarters
Hong Kong